Published in J Neurol on May 06, 2011
The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis (2013) 0.85
Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J Neurol (2015) 0.82
Pharmacotherapy of essential tremor. J Cent Nerv Syst Dis (2013) 0.81
Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna) (2015) 0.77
Cardiac sympathetic denervation in Parkinson's disease patients with SWEDDs. Neurol Sci (2012) 0.77
Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease. Eur J Nucl Med Mol Imaging (2015) 0.77
Screening for dopa-responsive dystonia in patients with Scans Without Evidence of Dopaminergic Deficiency (SWEDD). J Neurol (2014) 0.75
Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses. Neuroimage Clin (2016) 0.75
Impact of subcortical white matter lesions on dopamine transporter SPECT. J Neural Transm (Vienna) (2013) 0.75
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord (1998) 8.77
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry (1998) 2.24
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry (2005) 1.83
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Essential tremor--neurodegenerative or nondegenerative disease towards a working definition of ET. Mov Disord (2009) 1.66
The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry (2010) 1.53
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.51
Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord (2007) 1.44
Association between essential tremor and Parkinson's disease. Ann Neurol (1985) 1.33
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med (2001) 1.28
Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord (2003) 1.23
Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol (2005) 1.20
(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol (2004) 1.19
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord (2004) 1.12
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology (2003) 1.09
[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm (Vienna) (1998) 1.07
Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna) (2004) 1.05
One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med (1999) 1.00
Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med (2001) 0.99
Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun (2006) 0.95
Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord (2003) 0.94
Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord (2008) 0.94
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett (2002) 0.94
Olfaction testing in patients with tremor-dominant Parkinson's disease: is this a distinct condition? Mov Disord (2005) 0.90
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun (2005) 0.89
123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci (2003) 0.88
Preliminary remarks on the L-dopa therapy of dystonia. Neurology (1970) 0.86
Is there a relationship between Parkinson's disease and essential tremor? Clin Neuropharmacol (1993) 0.85
Torsion dystonia and spasmodic torticollis--results of treatment with L-dopa. Neurology (1970) 0.82
Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med (1996) 0.79
Levodopa can worsen tremor associated with dystonia. Mov Disord (2006) 0.75
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Sex and the risk of restless legs syndrome in the general population. Arch Intern Med (2004) 2.43
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int (2010) 2.27
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol (2012) 2.02
Body weight in patients with Parkinson's disease. Mov Disord (2006) 1.89
Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (2011) 1.88
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord (2009) 1.62
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev (2002) 1.46
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One (2008) 1.29
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet (2011) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol (2002) 1.23
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp (2011) 1.17
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol (2014) 1.12
Pathophysiological concepts of restless legs syndrome. Mov Disord (2007) 1.12
Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med (2011) 1.12
Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004) 1.12
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol (2006) 1.11
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord (2011) 1.10
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med (2008) 1.07
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med (2007) 1.06
Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol (2012) 1.05
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (Vienna) (2012) 1.04
Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics (2008) 1.03
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord (2005) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett (2004) 0.99
Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology (2007) 0.99
Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol (2002) 0.99
State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord (2007) 0.98
Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med (2010) 0.97
Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem (2007) 0.96
An automatic method for scoring leg movements in polygraphic sleep recordings and its validity in comparison to visual scoring. Sleep (2004) 0.96
Behavioral changes in unilaterally 6-hydroxy-dopamine lesioned rats after transplantation of differentiated mouse embryonic stem cells without morphological integration. Stem Cells (2004) 0.96
The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov Disord (2013) 0.94
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord (2013) 0.94
Affective and cognitive Theory of Mind in patients with parkinson's disease. Parkinsonism Relat Disord (2010) 0.94
T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology (2002) 0.94
Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord (2006) 0.93
T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. J Neurol (2007) 0.93
Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord (2013) 0.93
Radiosynoviorthesis (RSO): influencing factors and therapy monitoring. Ann Nucl Med (2008) 0.93
Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord (2008) 0.93
Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol (2005) 0.92
Contribution of the premotor cortex to consolidation of motor sequence learning in humans during sleep. J Neurophysiol (2010) 0.92
Nocturnal disturbances and restlessness in Parkinson's disease: using the Japanese version of the Parkinson's disease sleep scale-2. J Neurol Sci (2012) 0.92
Levodopa for restless legs syndrome. Cochrane Database Syst Rev (2011) 0.92
Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease? Sleep Med (2012) 0.92
Scoring sleep in neurological patients: the need for specific considerations. Sleep (2011) 0.91
European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol (2012) 0.91